Xiangxue Pharmaceutical's TAEST16001 Injection Listed as Breakthrough Therapy by CDE

Intelligent Finance APP News, Xiangxue Pharmaceutical (300147.SZ) announced that the TAEST16001 injection submitted by its subsidiary, GuangDong XIANGXUE LIFE SCIENCES LTD (referred to as "Xiangxue Life Sciences"), has been included in the list of breakthrough therapies by the Center for Drug Evaluation of the National Medical Products Administration. The proposed indication is for the treatment of soft tissue sarcoma with HLA-A*02:01 tissue genotype and positive expression of tumor antigen NY-ESO-1.